These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37738694)

  • 1. The incidence of tuberculosis recurrence: Impacts of treatment duration of and adherence to standard anti-tuberculous therapy.
    Lee CS; Ho CH; Liao KM; Wu YC; Shu CC
    J Infect Public Health; 2023 Nov; 16(11):1778-1783. PubMed ID: 37738694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six-month therapy for abdominal tuberculosis.
    Jullien S; Jain S; Ryan H; Ahuja V
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012163. PubMed ID: 27801499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
    Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014.
    Cornejo Garcia JG; Alarcón Guizado VA; Mendoza Ticona A; Alarcon E; Heldal E; Moore DAJ
    PLoS One; 2018; 13(12):e0206658. PubMed ID: 30513085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal duration of anti-TB treatment in patients with diabetes: nine or six months?
    Wang JY; Lee MC; Shu CC; Lee CH; Lee LN; Chao KM; Chang FY
    Chest; 2015 Feb; 147(2):520-528. PubMed ID: 25255302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Antituberculous Therapy on Uveitis Associated With Latent Tuberculosis.
    Tomkins-Netzer O; Leong BCS; Zhang X; Lightman S; McCluskey PJ;
    Am J Ophthalmol; 2018 Jun; 190():164-170. PubMed ID: 29604284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of childhood tuberculosis with a six month directly observed regimen of only two weeks of daily therapy.
    Al-Dossary FS; Ong LT; Correa AG; Starke JR
    Pediatr Infect Dis J; 2002 Feb; 21(2):91-7. PubMed ID: 11840073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial.
    Browne SH; Umlauf A; Tucker AJ; Low J; Moser K; Gonzalez Garcia J; Peloquin CA; Blaschke T; Vaida F; Benson CA
    PLoS Med; 2019 Oct; 16(10):e1002891. PubMed ID: 31584944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
    Park S; Jo KW; Lee SD; Kim WS; Shim TS
    Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nine- to Twelve-Month Anti-Tuberculosis Treatment Is Associated with a Lower Recurrence Rate than 6-9-Month Treatment in Human Immunodeficiency Virus-Infected Patients: A Retrospective Population-Based Cohort Study in Taiwan.
    Wang JY; Sun HY; Wang JT; Hung CC; Yu MC; Lee CH; Lee LN
    PLoS One; 2015; 10(12):e0144136. PubMed ID: 26633835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial.
    Padmapriyadarsini C; Bhavani PK; Natrajan M; Ponnuraja C; Kumar H; Gomathy SN; Guleria R; Jawahar SM; Singh M; Balganesh T; Swaminathan S
    BMJ Open; 2019 Mar; 9(3):e024363. PubMed ID: 30826761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research and control of relapse tuberculosis cases].
    Yamagishi F; Toyota M
    Kekkaku; 2009 Dec; 84(12):767-8. PubMed ID: 20077861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
    Schechter M; Zajdenverg R; Falco G; Barnes GL; Faulhaber JC; Coberly JS; Moore RD; Chaisson RE
    Am J Respir Crit Care Med; 2006 Apr; 173(8):922-6. PubMed ID: 16474028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania.
    Denti P; Jeremiah K; Chigutsa E; Faurholt-Jepsen D; PrayGod G; Range N; Castel S; Wiesner L; Hagen CM; Christiansen M; Changalucha J; McIlleron H; Friis H; Andersen AB
    PLoS One; 2015; 10(10):e0141002. PubMed ID: 26501782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.
    Yee D; Valiquette C; Pelletier M; Parisien I; Rocher I; Menzies D
    Am J Respir Crit Care Med; 2003 Jun; 167(11):1472-7. PubMed ID: 12569078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.